An Increasing prevalence of STDs and favorable international programs are boosting the Africa HIV Treatment Drugs Market | Forecast for 2023-2027|Technavio
Africa HIV Treatment Drugs Market is likely to experience steady growth because of the increasing prevalence of STDs and favorable international programs. Rising at a CAGR of 3.76%, the market is estimated to have an incremental growth of USD 321.6 Mn in revenue from 2023 to 2027.
Some of the leading companies contributing to this market growth are Alpha Pharma, Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Avacare Health, Boehringer Ingelheim International GmbH, Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson & Johnson, Merck & Co. Inc., SSI Diagnostica AS, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., etc. Our report includes the categorization of the core companies as pure play, category-focused, industry-focused, and diversified with a wider understanding of the business ecosystem.
Africa HIV Treatment Drugs Market Analysis at a Glance
As per a Technavio analyst: the “Quote” reason is expected to boost the growth of the HIV treatment drugs market in Africa
Lack of diagnosis of HIV access to modern medication and Social stigma associated with STDs are expected to hinder the growth of the market. However, an increase in awareness by various organizations and a growing focus on the elimination of mother-to-child transmission of HIV will have a positive impact on the HIV treatment drugs market in Africa during the forecast period.
Technavio’s analysis of the HIV treatment drugs market in Africa also includes: